TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15734771

Group type: EXPERIMENTAL
Intervention: Percutaneous left ventricular assist device (VAD) support
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intra-aortic balloon pump (IABP) support
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: VAD support
Number of subjects: 41

Group type: COMPARATOR
Intervention: IABP support
Number of subjects: 41
Study: 12487322

Group type: EXPERIMENTAL
Intervention: Andrographis paniculata extract SHA-10 fixed combination, Kan Jang, taken for 5 days
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 9796558

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (250 mg b.d. for 5 days)
Number of subjects: 684

Group type: COMPARATOR
Intervention: Clarithromycin (250 mg b.d. for 7 days)
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil
Number of subjects: 684

Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 684
Study: 8585285

Group type: EXPERIMENTAL
Intervention: Combined vaccine using immunopotentiating reconstituted influenza virosomes (IRIV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined vaccine using IRIV with all five vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined vaccine with halved quantity of Di‐Te antigen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Di‐Te vaccination in the combination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All vaccinations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alum‐adsorbed single vaccines
Number of subjects: 0
Study: 2495813

Group type: EXPERIMENTAL
Intervention: Alinidine 30 mg alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Alinidine 30 mg + Atenolol 25 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Alinidine 30 mg + Nifedipine retard 20 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Alinidine 30 mg + Glyceryl trinitrate 500 micrograms
Number of subjects: 18
Study: 1118271

Group type: EXPERIMENTAL
Intervention: Physical education program with an emphasis on recreational games
Number of subjects: 25

Group type: COMPARATOR
Intervention: Perceptual‐motor instruction
Number of subjects: 25
Study: 29703990

Group type: EXPERIMENTAL
Intervention: Topical pharyngeal anesthesia with propofol sedation
Number of subjects: 626

Group type: COMPARATOR
Intervention: Control group (propofol sedation without topical pharyngeal anesthesia)
Number of subjects: 626
Study: 27659698

Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg BID
Number of subjects: 0
Study: 25270901

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement in small aortic annulus tertile
Number of subjects: 1932

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement in large aortic annulus tertile
Number of subjects: 1932

Group type: COMPARATOR
Intervention: Transcatheter aortic valve replacement
Number of subjects: 1932

Group type: EXPERIMENTAL
Intervention: Nonrandomized continued access cohort in large aortic annulus tertile
Number of subjects: 1932

Group type: EXPERIMENTAL
Intervention: Large aortic annulus tertile
Number of subjects: 1932
Study: 22353786

Group type: EXPERIMENTAL
Intervention: Mometasone cream (0.1%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mometasone comparator (fatty cream with mometasone furoate 0.1%)
Number of subjects: 0
Study: 20201689

Group type: EXPERIMENTAL
Intervention: Blood transfusion therapy
Number of subjects: 204

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 204
Study: 18400807

Group type: EXPERIMENTAL
Intervention: Maraviroc (Pfizer's UK‐427857, Selzentry or Celsentri)
Number of subjects: 0

Group type: COMPARATOR
Intervention: R5 virus determination test (tropism test)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternative assays
Number of subjects: 0
Study: 16385907

Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 0
Study: 12638646

Group type: EXPERIMENTAL
Intervention: SSRI antidepressants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 0
Study: 11239615

Group type: EXPERIMENTAL
Intervention: MPA/E(2)C (Lunelle Monthly Contraceptive Injection)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other oral contraceptives
Number of subjects: 0

Group type: COMPARATOR
Intervention: NET/EE (Ortho-Novum 7/7/7)
Number of subjects: 0
Study: 8986246

Group type: EXPERIMENTAL
Intervention: E.P.D. (Enzyme Potentiated Desensitization) immunotherapy, administered via intradermal injection at extremely low doses once a year for seasonal allergies and twice a year for non-seasonal allergies
Number of subjects: 35
Study: 1592650

Group type: EXPERIMENTAL
Intervention: Adjuvant portal infusion (5‐Fluorouracil, Mitomycin C)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Radical surgery alone
Number of subjects: 533
Study: 6693604

Group type: EXPERIMENTAL
Intervention: 0.3% anthralin ointment for 10 minutes daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional strength (0.1%-0.5%) anthralin ointment overnight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High concentration anthralin (0.5%-3%) for short contact periods of 10 minutes daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical steroid, difluorosone diacetate
Number of subjects: 0
Study: 30810273

Group type: EXPERIMENTAL
Intervention: Signing intervention group (mothers received signing instructions)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group (mothers did not receive signing instructions)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Signing intervention group
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 228
Study: 29164181

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (continuous wavelength of 2,940 nm)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Scalpel technique
Number of subjects: 20
Study: 27005817

Group type: EXPERIMENTAL
Intervention: G allele carriers of rs13431554
Number of subjects: 674
Study: 24910422

Group type: EXPERIMENTAL
Intervention: Community-based skill-building intervention
Number of subjects: 75

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 75
Study: 23018805

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 654
Study: 19882176

Group type: EXPERIMENTAL
Intervention: Single 150-mg oral dose of casopitant
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: 3-day IV/oral casopitant
Number of subjects: 810

Group type: COMPARATOR
Intervention: Control (IV ondansetron/dexamethasone alone)
Number of subjects: 810

Group type: COMPARATOR
Intervention: Single oral casopitant vs Control
Number of subjects: 810

Group type: COMPARATOR
Intervention: 3-day IV/oral casopitant vs Control
Number of subjects: 810
Study: 16889952

Group type: EXPERIMENTAL
Intervention: Flixotide Diskus (FP) 500-0 mcg/day
Number of subjects: 282

Group type: COMPARATOR
Intervention: Pulmicort Turbuhaler (BUD) 800-0 mcg/day
Number of subjects: 282
Study: 16529064

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors (rivastigmine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ginkgo biloba
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selegiline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Piracetam
Number of subjects: 0
Study: 12439737

Group type: EXPERIMENTAL
Intervention: Antihypertensive medication
Number of subjects: 42418

Group type: EXPERIMENTAL
Intervention: Genotyping variants in hypertension genes
Number of subjects: 42418
Study: 10715673

Group type: EXPERIMENTAL
Intervention: 14-day primaquine regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-day primaquine regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: No primaquine treatment
Number of subjects: 0
Study: 8557961

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg once a day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Amiloride+hydrochlorothiazide (2.5/25 mg once a day)
Number of subjects: 41
Study: 1810358

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Dothiepin
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Fluvoxamine and Dothiepin
Number of subjects: 52
Study: 6863363

Group type: EXPERIMENTAL
Intervention: Intravenous regional guanethidine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Intravenous regional reserpine
Number of subjects: 7
Study: 30548977

Group type: EXPERIMENTAL
Intervention: Inhaled loxapine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Intramuscular haloperidol + lorazepam
Number of subjects: 47
Study: 30457119

Group type: EXPERIMENTAL
Intervention: Fast motion-including dose reconstruction for proton pencil beam scanning
Number of subjects: 10

Group type: COMPARATOR
Intervention: 4DCT motion assumption
Number of subjects: 10
Study: 26924621

Group type: EXPERIMENTAL
Intervention: Biological mesh reinforcement during stoma closure
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard closure without mesh
Number of subjects: 90
Study: 23466111

Group type: EXPERIMENTAL
Intervention: Yoga intervention (supervised yoga training thrice a week for 4 weeks, followed by home practice for 2 months)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Wait-list group (control)
Number of subjects: 29
Study: 21565149

Group type: EXPERIMENTAL
Intervention: Indoor Residual Spray (IRS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insecticide Treated Bednets (ITN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ITN use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sleeping under an ITN
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community participation in environmental and larval habitat management activities
Number of subjects: 0
Study: 19300110

Group type: EXPERIMENTAL
Intervention: Higher intensity training (66% of heart rate reserve)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Lower intensity training (33% of heart rate reserve)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (sedentary period)
Number of subjects: 39
Study: 17052140

Group type: EXPERIMENTAL
Intervention: Self-report questionnaire
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Adherence interview item
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Electronic medication monitoring
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Second-order factor model of adherence
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Single-method models (one method of assessing adherence)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Models including both self-report and electronic monitoring
Number of subjects: 323
Study: 12737331

Group type: EXPERIMENTAL
Intervention: Active treatment (low-level laser therapy)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 35
Study: 11059532

Group type: EXPERIMENTAL
Intervention: i.v. polyethylene glycol‐treated human immunoglobulin at 200 mg/kg per day
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: i.v. polyethylene glycol‐treated human immunoglobulin at 400 mg/kg per day
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: freeze‐dried sulfonated human immunoglobulin at 200 mg/kg per day
Number of subjects: 451
Study: 9080749

Group type: EXPERIMENTAL
Intervention: Resilient mandibular bar-retained overdenture on two implants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implants in the maxilla splinted by a rigidly cast bar
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overdenture therapy
Number of subjects: 0
Study: 7680544

Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 81

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 81
Study: 2439821

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg p.o.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Bopindolol (1 mg p.o.)
Number of subjects: 10
Study: 29373493

Group type: EXPERIMENTAL
Intervention: Traditional sorghum and millet foods (thick porridges and millet couscous)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Rice, potato, or pasta
Number of subjects: 14
Study: 26999639

Group type: EXPERIMENTAL
Intervention: PSV with GF100%
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: NAVA with GF100%
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PSV with GF0%
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: NAVA with GF0%
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Increasing carbon dioxide extraction by ECMO
Number of subjects: 8
Study: 24394187

Group type: EXPERIMENTAL
Intervention: Hepatitis B virus (HBV) envelope DNA vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (without vaccination)
Number of subjects: 0
Study: 21628602

Group type: EXPERIMENTAL
Intervention: NAP/ESO tablet (500 mg EC naproxen + 20 mg non-EC esomeprazole magnesium)
Number of subjects: 40

Group type: COMPARATOR
Intervention: EC naproxen tablet alone
Number of subjects: 40

Group type: COMPARATOR
Intervention: EC esomeprazole magnesium capsule alone
Number of subjects: 40

Group type: COMPARATOR
Intervention: EC naproxen tablet + EC esomeprazole magnesium capsule
Number of subjects: 40
Study: 20032480

Group type: EXPERIMENTAL
Intervention: Atole (gruel containing protein and energy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fresco (low-energy drink containing no protein)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal nutritional status and supplement intake
Number of subjects: 0
Study: 18222355

Group type: EXPERIMENTAL
Intervention: Intensive statin therapy
Number of subjects: 1778

Group type: COMPARATOR
Intervention: Moderate statin therapy
Number of subjects: 1778

Group type: EXPERIMENTAL
Intervention: Intensive and moderate statin therapy
Number of subjects: 1778
Study: 19615315

Group type: EXPERIMENTAL
Intervention: Modified Danggui Sini Decoction
Number of subjects: 72

Group type: COMPARATOR
Intervention: Cilostazol
Number of subjects: 72
Study: 15009510

Group type: EXPERIMENTAL
Intervention: Single light pulse (5000 lux for 3 hr)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single melatonin pill (5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of light pulse and melatonin
Number of subjects: 0
Study: 11587165

Group type: EXPERIMENTAL
Intervention: 5 mg/day of oral amlodipine
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 5 mg of amlodipine (baseline) + 5 mg of amlodipine (additional)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 5 mg of amlodipine (baseline) + 25 mg of hydrochlorothiazide (HCTZ)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 5 mg of amlodipine (baseline) + 20 mg of benazepril
Number of subjects: 47
Study: 9396419

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 512

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 512
Study: 7988255

Group type: EXPERIMENTAL
Intervention: Functional Living Index‐Cancer (FLIC) administered to patients
Number of subjects: 438

Group type: COMPARATOR
Intervention: Short course of chemotherapy
Number of subjects: 438
Study: 3108159

Group type: EXPERIMENTAL
Intervention: Carbohydrate in combination with fat emulsions (fat group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High carbohydrate solutions (carbohydrate group)
Number of subjects: 0
Study: 12561621

Group type: EXPERIMENTAL
Intervention: Dietary intervention for 3 months
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 47
Study: 31365976

Group type: EXPERIMENTAL
Intervention: Peramivir
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 30126630

Group type: EXPERIMENTAL
Intervention: Closed incision negative pressure therapy (ciNPT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Adhesive strips
Number of subjects: 51
Study: 26047766

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs (0.315 g per capsule, 3 capsules daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mineral oil (placebo)
Number of subjects: 50
Study: 23465551

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No remote ischemic preconditioning (n = 12)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 24
Study: 22262230

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 600 mg every 12 hours for 4 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg every 24 hours for 4 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hydration only (Control group)
Number of subjects: 120
Study: 20522656

Group type: EXPERIMENTAL
Intervention: Comprehensive specific care plan with standardised twice yearly consultation
Number of subjects: 1131

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1131
Study: 16929239

Group type: EXPERIMENTAL
Intervention: Arginine-enhanced formula (17 g/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Isocaloric, isonitrogenous enteral formula
Number of subjects: 72
Study: 16138795

Group type: EXPERIMENTAL
Intervention: Home care treatment delivered by primary care teams
Number of subjects: 55

Group type: COMPARATOR
Intervention: Hospital treatment as usual
Number of subjects: 55
Study: 11856154

Group type: EXPERIMENTAL
Intervention: Local therapy plus six cycles of chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) followed by tamoxifen 20 mg daily for 5 years
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (historical control population who never received systemic therapy)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Patients with negative axillary lymph nodes
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Patients with positive and negative hormone receptor status
Number of subjects: 45
Study: 10550090

Group type: EXPERIMENTAL
Intervention: Personalised computer-based information system
Number of subjects: 525

Group type: COMPARATOR
Intervention: General computer-based information system
Number of subjects: 525

Group type: COMPARATOR
Intervention: Information booklets
Number of subjects: 525
Study: 7869147

Group type: EXPERIMENTAL
Intervention: Oral instructions by certified nurse-midwife in addition to written instructions (Group 2, n = 45)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Written postpartum instructions only (Group 1, n = 55)
Number of subjects: 100
Study: 2673079

Group type: EXPERIMENTAL
Intervention: 200 mg daily dose of hydroxychloroquine sulphate
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 400 mg daily dose of hydroxychloroquine sulphate
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study: 347232

Group type: EXPERIMENTAL
Intervention: Lactose hydrolysed milk
Number of subjects: 50

Group type: COMPARATOR
Intervention: Full-cream milk powder (control)
Number of subjects: 50
Study: 31025200

Group type: EXPERIMENTAL
Intervention: Temporal bisection task with hands near test stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal time estimation task with hands near test stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Temporal bisection task with hands far from test stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verbal time estimation task with hands far from test stimuli
Number of subjects: 0
Study: 25966679

Group type: EXPERIMENTAL
Intervention: Periarticular infiltrations and continuous post-operative intra-articular infusion of local anaesthetics (PIAC group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Combined femoral (continuous) and sciatic (single-shot) nerve block (CFNB group)
Number of subjects: 50
Study: 25908190

Group type: EXPERIMENTAL
Intervention: RPE/C (facemask protraction after RPE/C)
Number of subjects: 24

Group type: COMPARATOR
Intervention: RPE (facemask protraction after RPE)
Number of subjects: 24
Study: 25037695

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg subcutaneously every 2 weeks (Q2W), with potential up-titration to 150 mg Q2W at week 12 if LDL-C was ≥ 70 mg/dL at week 8.
Number of subjects: 103

Group type: COMPARATOR
Intervention: Ezetimibe 10 mg/day.
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg Q2W before up-titration at week 12.
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Injection site reactions for Alirocumab.
Number of subjects: 103

Group type: COMPARATOR
Intervention: Injection site reactions for Ezetimibe.
Number of subjects: 103
Study: 21750917

Group type: EXPERIMENTAL
Intervention: 500 ppm F dentifrice
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 500 ppm F plus fTCP dentifrice
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1,100 ppm F dentifrice
Number of subjects: 30
Study: 19574013

Group type: EXPERIMENTAL
Intervention: 1000 mg of MMF (mycophenolate mofetil)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 750 mg bid of MMF (mycophenolate mofetil)
Number of subjects: 17
Study: 17640366

Group type: EXPERIMENTAL
Intervention: Signs of Suicide (SOS) prevention program
Number of subjects: 4133

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4133
Study: 15022114

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy with Gemcitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study: 15015973

Group type: EXPERIMENTAL
Intervention: Thiopental-fentanyl-sevoflurane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propofol-fentanyl-sevoflurane
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Thiopental (in vitro)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fentanyl (in vitro)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propofol (in vitro)
Number of subjects: 20
Study: 12500876

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated grooved implants
Number of subjects: 829

Group type: COMPARATOR
Intervention: Hydroxyapatite grooved and screw implants
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated cylinder
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated cylinder and grooved implants
Number of subjects: 829

Group type: COMPARATOR
Intervention: Non-hydroxyapatite-coated implants
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated press-fit cylinder
Number of subjects: 829
Study: 9249283

Group type: EXPERIMENTAL
Intervention: Jewelweed extract
Number of subjects: 10

Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 10